Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Breast Neoplasms 222Carcinoma, Non-Small-Cell Lung 219Prostatic Neoplasms 156Multiple Myeloma 142Neoplasms 133Colorectal Neoplasms 118Leukemia, Myeloid, Acute 110Lung Neoplasms 103Neoplasm Metastasis 96Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 86Lymphoma 81Melanoma 78Pancreatic Neoplasms 74Triple Negative Breast Neoplasms 72Ovarian Neoplasms 66Sarcoma 65Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Lymphoma, Non-Hodgkin 55Stomach Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Hematologic Neoplasms 52Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Urinary Bladder Neoplasms 46

Interventions

darolutamide 1bicalutamide 1abemaciclib 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Bulbo-Spinal Atrophy, X-Linked × 90 days × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06365788 2026-04-01

ABBICAR

Universitaire Ziekenhuizen KU Leuven

Phase 2 Recruiting
53 enrolled
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡